The Patent Trial and Appeal Board (PTAB): Role and Procedures
The Patent Trial and Appeal Board is an administrative tribunal within the U.S. Patent and Trademark Office that adjudicates patent validity disputes and hears appeals from USPTO examination decisions. Established by the America Invents Act (AIA) in 2011, PTAB consolidated and expanded the USPTO's internal adjudicative functions under a single body with authority over three major post-grant trial proceedings. Understanding PTAB's jurisdiction, procedures, and decision standards is essential for patent owners, challengers, and practitioners navigating the regulatory context for patent law.
Definition and scope
PTAB operates under 35 U.S.C. §§ 6, 311–329 and is composed of administrative patent judges (APJs) appointed by the Secretary of Commerce. The Board's authority spans two distinct functional areas: conducting contested inter partes trial proceedings challenging the validity of issued patents, and adjudicating appeals from adverse decisions by USPTO examiners during prosecution.
PTAB's three principal trial proceedings are:
- Inter Partes Review (IPR) — Challenges issued patent claims based on prior art patents or printed publications under 35 U.S.C. §§ 102 and 103. Petitions must be filed within one year of service of an infringement complaint (35 U.S.C. § 315(b)).
- Post-Grant Review (PGR) — Available for any ground of invalidity, but only during the first nine months after a patent's grant or reissuance (35 U.S.C. § 321).
- Covered Business Method Review (CBM) — A transitional program for business-method patents, which sunset in September 2020 under AIA § 18.
The Board also hears appeals from final rejections issued by examiners under 35 U.S.C. § 134, as well as appeals in interference and derivation proceedings. Further details on inter partes review and post-grant review are covered in dedicated reference pages across this site.
How it works
PTAB proceedings follow a structured multi-phase process governed by 37 C.F.R. Part 42, the Board's primary procedural regulation (USPTO 37 C.F.R. Part 42).
Phase 1 — Petition and Preliminary Response:
A petitioner files a petition identifying each challenged claim, the grounds of challenge, and supporting evidence. The patent owner may file a preliminary response within 3 months. The Board then decides whether to institute a trial, applying a threshold standard that at least one challenged claim is more likely than not unpatentable (PGR) or that the petition raises a reasonable likelihood of prevailing on at least one claim (IPR) (35 U.S.C. §§ 314, 324).
Phase 2 — Trial:
If instituted, the proceeding advances to a 12-month trial period. Both parties submit evidence, including expert declarations. Limited discovery is permitted under 37 C.F.R. § 42.51. Each party may file written briefs, and an oral hearing is available upon request.
Phase 3 — Final Written Decision:
The Board issues a final written decision within 12 months of institution (extendable to 18 months for good cause under 35 U.S.C. § 316(a)(11)). The decision either cancels, confirms, or modifies the challenged claims.
PTAB applies the preponderance of the evidence standard in IPR and PGR proceedings. Claims are given their ordinary and customary meaning as understood by a person of ordinary skill in the art, following the Phillips construction standard adopted in rule changes effective November 2018 (USPTO Final Rule, 83 Fed. Reg. 51340).
Common scenarios
PTAB proceedings arise in four identifiable contexts:
Parallel litigation defense — A defendant served with a patent infringement complaint files an IPR petition within the one-year window, seeking to invalidate the asserted claims before a district court trial concludes. If the Board institutes review, the petitioner may seek a stay of the district court litigation.
Competitor clearance — A company launching a product potentially covered by a competitor's patent files a PGR petition during the nine-month window after the patent issues, targeting claims on any invalidity ground, including § 101 subject-matter eligibility under the framework articulated in 35 U.S.C. § 101.
Patent prosecution appeals — An applicant whose claims were finally rejected by a USPTO examiner appeals to PTAB under 35 U.S.C. § 134(a). The Board reviews the examiner's rejection on the record and may affirm, reverse, or remand. Details on this pathway are covered under appeals from USPTO rejections.
Invalidity challenges in pharmaceutical disputes — Generic drug manufacturers use IPR to challenge branded pharmaceutical patents, a practice that intensified following AIA enactment. This intersection with Hatch-Waxman litigation is addressed in the pharmaceutical patent law reference.
Decision boundaries
PTAB jurisdiction has defined limits established by statute and Federal Circuit precedent.
Estoppel — A petitioner who receives a final written decision in an IPR is estopped under 35 U.S.C. § 315(e) from raising in subsequent district court or ITC proceedings any ground that was raised or reasonably could have been raised during the IPR.
Discretionary denial — Under 35 U.S.C. § 314(a), the Board retains discretion to deny institution even when the petition meets the substantive threshold. The Board has articulated factors for discretionary denial in the context of parallel litigation, most prominently in Apple Inc. v. Fintiv, Inc. (PTAB 2020), which created a six-factor balancing framework. USPTO has issued subsequent Director Guidance modifying Fintiv's application.
IPR vs. PGR — scope distinction:
| Proceeding | Filing window | Grounds available | Threshold standard |
|---|---|---|---|
| IPR | Post-nine months from grant; within one year of complaint | §§ 102, 103 (prior art only) | Reasonable likelihood of prevailing |
| PGR | Within nine months of grant | Any invalidity ground (§§ 101–103, 112) | More likely than not unpatentable |
Appellate review — Final written decisions are appealable to the United States Court of Appeals for the Federal Circuit under 35 U.S.C. § 319. The Federal Circuit reviews legal questions de novo and factual findings for substantial evidence. Patent owners who successfully preserve claims at PTAB may still face invalidity challenges under patent invalidity defenses in district court litigation, as PTAB estoppel binds only the petitioner.
The patent litigation process and PTAB post-grant proceedings operate as parallel but distinct tracks. A comprehensive overview of all patent procedures is available on the patent law authority index.